louisiana glp-1 lawsuit Louisiana state insurance plans spend $200 million a year on GLP-1 drugs • Louisiana Illuminator semaglutide digestive blockage law firm

Obesity and diabetes were the strongest predictors, with patients exhibiting obesity having 3.5 times higher odds and those with diabetes having 5.8 times higher odds of being prescribed GLP-1 therapy

Collectively, our data show that GIPR agonism and antagonism decrease body weight and food intake via different neuronal mechanisms, with GIPR antagonism, unlike agonism, depending on GLP-1R signalling but not GIPR signalling in either GABAergic or peripheral neurons

10.5530/ijopp.11.1.10 201 RolfeH

Clinical trials have reported average weight reductions of approximately 3 to 5 kilograms with shorter acting agents, while higher dose, longer acting formulations have produced more substantial losses exceeding 10 kilograms in some patient populations

Factors That Affect How Quickly GLP-1 Medications Work Multiple variables influence the speed and magnitude of response to GLP-1 receptor agonist therapy